Navigation Links
Regado Biosciences to Present at the Annual UBS Global Life Sciences Conference in New York City
Date:9/14/2011

and the second being its complementary active control agent (anivamersen, a.k.a. RB007).  Anivamersen can be used to selectively completely or partially reverse the anticoagulant effect of pegnivacogin.  REG1, having recently completed phase 2b clinical development (the RADAR trial), is intended for application in arterial thrombosis indications, such as Acute Coronary Syndrome patients undergoing Percutaneous Coronary Intervention.  A clinical program in Open Heart Surgery [including coronary artery bypass grafting (CABG) and valve repair/replacement] is also under development.  REG2, Regado's second product candidate, consists of a subcutaneously administered depot formulation of pegnivacogin paired with the IV bolus formulation of anivamersen.  REG2 recently completed single escalating dose phase 1 clinical testing (the first successful subcutaneous application of an aptamer in humans) and is planned to be studied in a multiple escalating dose clinical trial in 2011.  It is intended for use in venous thrombosis indications such as venous thromboembolism (VTE) prophylaxis in patients undergoing abdominal surgery.  REG3, Regado's third program, consists of a specific GPVI inhibitor and its active control agent (RB571 and RB515, respectively).  REG3 is planned to enter phase 1 human clinical testing in 2011 and will be indicated for antiplatelet therapy.  Information pertaining to Regado's clinical programs may be obtained at www.clinicaltrials.gov.

ABOUT APTAMERS

Pegnivacogin is a member of a class of compounds called aptamers.  Aptamers are single stranded oligonucleotides that adopt a specific conformation enabling direct, specific inhibition of the targeted protein.  A key unique feature of aptamers derives from the fact that they are formed from nucleic acids.  As such, their pharmacologic activity can be controlled by a matched, complem
'/>"/>

SOURCE Regado Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
2. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
3. Regado Biosciences, Inc. Announces Presentation of the Results of the RADAR Phase 2b Clinical Trial of Its Anticoagulant System REG1 at the i2 Summit During the American College of Cardiology 2011 60th Annual Scientific Session & Expo in New Orleans
4. Regado Biosciences to Present at the 2011 RBC Capital Markets Healthcare Conference in New York City
5. Regado Biosciences, Inc. Introduces REG3, a Novel Aptamer-Based Inhibitor of Glycoprotein VI and its Matched Active Control Agent, at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
6. Regado Biosciences, Inc. Presents Pharmacokinetic and Pharmacodynamic (PK/PD) Substudy Results From its Phase 2b RADAR Trial at the American Heart Association (AHA) Scientific Sessions 2010 Meeting
7. Regado Biosciences, Inc. Presents Two Abstracts on the Subcutaneous Depot Formulation of Pegnivacogin, a Nuclease-Stabilized RNA Aptamer, Direct Factor IXa Inhibitor and Part of the REG2 Anticoagulant System, at the American Heart Association (AHA)
8. Regado Biosciences to Present at the IMPACT 2010 Conference in Philadelphia, Pennsylvania
9. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
10. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
11. Regado Biosciences to Present at the 2010 Wells Fargo Healthcare Conference on June 24, 2010 in Boston, Massachusetts
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... July 11, 2014 According ... by Composition of Material, Application (Healthcare, Homeland security, ... Product (Personal Instrument, Hand-Held Instruments, Fixed, and Installed ... to 2013 - 2020", published by MarketsandMarkets, the Scintillator Market ... 5.62% from 2014 to 2020, and reach $479.16 ...
(Date:7/11/2014)... , July 11, 2014 ... Market Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, ... Growth, Trends and Forecast, 2013-2019" the global endoscopy devices ... and is expected to grow at a CAGR of ... value of USD 36.9 billion in 2019. ...
(Date:7/10/2014)... 2014  Major advances in radiation therapy and ... highlighted in a three-day Oncology Summit taking place ... 2014.  Renowned national and international cancer experts from seven ... exchange knowledge on modern technologies making treatment for ... The Summit will address a wide ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... May 22, 2012 Prosolia, Inc. and AB SCIEX announced ... technologies developed by Dr. Gary Van Berkel and his colleagues ... an innovator in the field of mass spectrometry and is ... field.  The agreement provides Prosolia a license to a portfolio ...
... May 21, 2012  BD (Becton, Dickinson and Company) (NYSE: ... company, and Heart to Heart International, a humanitarian medical ... joint volunteer initiative to strengthen healthcare in Haiti.  A ... will build upon the progress made by their colleagues ...
Cached Medicine Technology:Prosolia and AB SCIEX reach licensing agreement 2BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti 2BD and Heart to Heart International Collaborate on Second Volunteer Service Trip to Help Improve Healthcare in Haiti 3
(Date:7/11/2014)... (PRWEB) July 11, 2014 Utilizing the ... own, Dr. William Koenig, has topped a record number ... he has performed over 400 successful procedures without the ... Koenig is well known across the country for his ... safety record has long been the foundation for numerous ...
(Date:7/11/2014)... 2014 (HealthDay News) -- Children who have emergency ... complications and potentially even death than those who ... However, the Johns Hopkins researchers noted that ... researchers analyzed data on nearly 440,000 simple emergency ... over a 22-year period. The surgeries are ...
(Date:7/11/2014)... The report “Probiotics Market by Products (Functional Foods, ... Therapeutic, Preventive Health Care) & Ingredients (Lactobacilli, Bifidobacteria, ... ” defines and segments the global probiotics market ... value of probiotic products and ingredients. The report ... the global market with an analysis of trends, ...
(Date:7/11/2014)... 2014 Global enterprises today are shifting ... day-to-day management activities. Managed services offer these global enterprises ... economic slowdown resulted into rising operational costs to companies. ... considered to be the global market driver for expanding ... global managed services market is estimated to grow from ...
(Date:7/11/2014)... Toledo, Ohio (PRWEB) July 11, 2014 ... (Morgenson 7/10/14) and FiercePharma (Weintraub 7/11/14), a significant number ... in blood sugar, abdominal issues and even death from ... exposed. , According to the Times report , ... events in 2013 reported by patients was almost 14% ...
Breaking Medicine News(10 mins):Health News:Rochester Surgeon Hits Milestone with Keller Funnel 2Health News:Emergency Surgeries on Weekends Riskier for Kids: Study 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 2Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 3Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 4Health News:Probiotic Ingredient Market worth $1,732.8 Million by 2019 - A Report by MarketsandMarkets 5Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3
... like pushing an elevator button or reaching for a cup ... or right hand will do the job. But the left ... of the brain receives magnetic stimulation, according to new research ... applied transcranial magnetic stimulation (TMS) to the posterior parietal cortex ...
... spiritually and medicine, will be the featured speaker at the ... Annual R.J. DeBottis Memorial Lecture on Aging on Monday, Nov. ... honored to host Dr. Koenig who is a pioneer in ... all ages," said Ira Colby, dean of the UH GCSW. ...
... HealthDay Reporter , MONDAY, Sept. 27 (HealthDay ... children exposed to tobacco ads at all, and wants ... for erectile dysfunction drugs and other prescription medications. ... in its new policy statement, "Children, Adolescents, Substance Abuse, ...
... Therapeutics, Inc. is presenting new data in five posters ... with the company,s radioprotectant Ex-RAD at the 56th Annual ... in Maui, Hawaii. In vivo studies show that ... survival versus placebo-treated groups in mice exposed to lethal ...
... healthy lifestyle habits such as eating fruits and vegetables ... their health because they tend to consume large amounts ... research at The Michael & Susan Dell Center for ... Center at Houston (UTHealth). "Children and parents ...
... appropriate training and support they need to help people who ... levels of care. Those are the key findings of ... the University of Nottingham, UK, and published in the October ... Nursing. Staff nurse Jo McHale and lecturer Anne ...
Cached Medicine News:Health News:Right or left? Brain stimulation can change which hand you favor 2Health News:Dr. Harold G. Koenig to speak at R.J. DeBottis Lecture on Aging, Nov. 8 2Health News:Pediatricians Want to Restrict Ads for Tobacco, Booze, Viagra 2Health News:Pediatricians Want to Restrict Ads for Tobacco, Booze, Viagra 3Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 2Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 3Health News:Sugary sports drinks mistakenly associated with being healthy, say UTHealth researchers 2Health News:Medical profession needs special training to handle self-harm, says international review 2Health News:Medical profession needs special training to handle self-harm, says international review 3
... TOX/See™ is a 1-step, hand-held, point-of-care device ... metabolites in human urine. The TOX/See device ... commonly abused drugs in 3 to 8 minutes ... Each TOX/See cassette is individually packaged to maximize ...
... The Carpal Solution offers relief from CTS ... is different from other over-the-counter CTS treatments. ... Worn during sleep, the Carpal Solution gently ... Carpal Tunnel and eliminates hand pain, numbness ...
... Linearity is a whole blood formulation ... range of the most popular glucose ... of using a control matrix that ... is packaged in ready-to-use dropper vials ...
... ESR-10 Manual Rack is a manual ... the erythrocyte sedimentation rate (ESR) of ... 1.2ml Streck ESR-Vacuum Tubes. The rack ... simultaneously. The ESR-10 Manual Rack exhibits ...
Medicine Products: